![Radium-223 [Xofigo] – (Targeted Radiotherapy for Bone Metastases in Prostate Cancer)](data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E)
Introduction
Radium-223, sold under the trade name Xofigo, is a targeted radiotherapy treatment for men with advanced prostate cancer that has spread to the bones. It is designed to alleviate pain, slow disease progression, and improve quality of life in patients with symptomatic bone metastases.
Purpose
- Treats metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases.
- Reduces bone pain and skeletal-related complications.
- Prolongs survival in men with advanced disease affecting the bones.
How It Works
Radium-223 mimics calcium and selectively targets areas of increased bone turnover, such as bone metastases. Once there, it emits high-energy alpha particles that damage cancer cells while sparing surrounding healthy tissue.
Usage
- Administered as an intravenous injection every four weeks for up to six doses.
- Each injection is given in a clinical setting by trained healthcare providers.
Considerations
- Common side effects include nausea, diarrhea, and mild bone marrow suppression.
- Rare but serious risks include severe anemia, neutropenia, or thrombocytopenia.
- Not indicated for patients with visceral metastases or those requiring chemotherapy at the same time.
At Crossroads Urology
At Crossroads Urology, Radium-223 is an integral part of our approach to managing advanced prostate cancer with bone involvement. Our providers work closely with oncology specialists to tailor treatment plans and monitor for side effects.
Conclusion
Radium-223 [Xofigo] offers a targeted and effective therapy for men with bone metastases from prostate cancer. Contact Crossroads Urology today to learn more about this innovative treatment and how it can improve your quality of life.
